Medifast, Inc.

NYSE:MED Rapport sur les actions

Capitalisation boursière : US$206.7m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Medifast Gestion

Gestion contrôle des critères 3/4

Le PDG Medifast's est Dan Chard, nommé en Oct2016, a un mandat de 7.83 ans. La rémunération annuelle totale est $ 7.04M, composée du salaire de 14.2% et des bonus 85.8%, y compris les actions et options de la société. détient directement 1.46% des actions de la société, d'une valeur de $ 3.02M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.5 ans et 7.8 ans.

Informations clés

Dan Chard

Directeur général

US$7.0m

Rémunération totale

Pourcentage du salaire du PDG14.2%
Durée du mandat du directeur général7.8yrs
Propriété du PDG1.5%
Durée moyenne d'occupation des postes de direction4.5yrs
Durée moyenne du mandat des membres du conseil d'administration7.8yrs

Mises à jour récentes de la gestion

Recent updates

Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing

Jun 26

Medifast: Significant Undervaluation Even As Struggles Persist

May 24

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

Medifast: Cheap Valuation, Uncertain Future

Mar 20

Medifast Is Getting Attractive

Mar 07

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Feb 22
Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Jan 20

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Dec 09
Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Nov 24

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Nov 21
Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Nov 09

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Oct 09

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Aug 04

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Jul 26
Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Jul 21

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Jul 05
Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast: In Survival Mode Against Diet Pills And The Recession

Jun 14

Medifast Holds Value During Headwinds

May 28

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Feb 21

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

Feb 07

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Jan 19
At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Medifast declares $1.64 dividend

Dec 08

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Dec 01
A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 10
Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Nov 08
One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy

Nov 06

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Oct 20
What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Sep 18
We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Medifast declares $1.64 dividend

Sep 08

Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Sep 02
Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Aug 21

Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year

Aug 09
Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year

Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?

Jul 27
Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Jul 12
What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Analyse de la rémunération des PDG

Comment la rémunération de Dan Chard a-t-elle évolué par rapport aux bénéfices de Medifast?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

US$29m

Mar 31 2024n/an/a

US$68m

Dec 31 2023US$7mUS$1m

US$99m

Sep 30 2023n/an/a

US$120m

Jun 30 2023n/an/a

US$133m

Mar 31 2023n/an/a

US$142m

Dec 31 2022US$6mUS$981k

US$144m

Sep 30 2022n/an/a

US$151m

Jun 30 2022n/an/a

US$157m

Mar 31 2022n/an/a

US$165m

Dec 31 2021US$7mUS$914k

US$164m

Sep 30 2021n/an/a

US$158m

Jun 30 2021n/an/a

US$150m

Mar 31 2021n/an/a

US$125m

Dec 31 2020US$6mUS$909k

US$103m

Sep 30 2020n/an/a

US$95m

Jun 30 2020n/an/a

US$76m

Mar 31 2020n/an/a

US$76m

Dec 31 2019US$5mUS$843k

US$78m

Sep 30 2019n/an/a

US$74m

Jun 30 2019n/an/a

US$72m

Mar 31 2019n/an/a

US$64m

Dec 31 2018US$2mUS$675k

US$56m

Sep 30 2018n/an/a

US$47m

Jun 30 2018n/an/a

US$40m

Mar 31 2018n/an/a

US$34m

Dec 31 2017US$2mUS$650k

US$28m

Rémunération vs marché: La rémunération totale de Dan ($USD 7.04M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.52M ).

Rémunération et revenus: La rémunération de Dan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Dan Chard (59 yo)

7.8yrs

Titularisation

US$7,039,062

Compensation

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Daniel Chard
Executive Chairman & CEO7.8yrsUS$7.04m1.46%
$ 3.0m
James Maloney
Chief Financial Officer4.1yrsUS$2.01m0.092%
$ 189.3k
Anthony Tyree
Chief Business Operations Officer2.6yrsUS$1.61m0.12%
$ 242.1k
Jason Groves
Executive VP12.8yrsUS$1.63m0.12%
$ 241.0k
Nicholas Johnson
Chief Field Operations Officer5.5yrsUS$1.70m0.095%
$ 197.1k
Jonathan MacKenzie
VP of Finance & Chief Accounting Officer2.9yrspas de données0.0050%
$ 10.3k
Steven Zenker
Vice President of Investor Relations1.4yrspas de donnéespas de données
Claudia Greninger
Chief Human Resources Officer4.8yrspas de donnéespas de données

4.5yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: L'équipe de direction de MED est considérée comme expérimentée (ancienneté moyenne 4.5 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Daniel Chard
Executive Chairman & CEO7.8yrsUS$7.04m1.46%
$ 3.0m
Jeffrey Brown
Lead Independent Director9.2yrsUS$263.42k0.15%
$ 302.8k
George Bray
Member of Scientific Advisory Boardno datapas de donnéespas de données
Michael Hoer
Independent Director6.2yrsUS$249.72k0.079%
$ 162.6k
Andrea Thomas
Independent Director5.2yrsUS$249.72k0.059%
$ 121.4k
John Foreyt
Member of Scientific Advisory Boardno datapas de donnéespas de données
Ming Xian
Independent Director6.2yrsUS$219.61kpas de données
Lawrence Cheskin
Chairman of Scientific Advisory Board15.8yrspas de donnéespas de données
Sylvia Rowe
Member of Scientific Advisory Boardno datapas de donnéespas de données
Scott Schlackman
Independent Director9.2yrsUS$252.44k0.073%
$ 151.1k
John Hayes
Member of Scientific Advisory Boardno datapas de donnéespas de données
Mark Messina
Member of Scientific Advisory Boardno datapas de donnéespas de données

7.8yrs

Durée moyenne de l'emploi

62.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de MED sont considérés comme expérimentés (ancienneté moyenne 7.8 ans).